Business Description
Corvus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Description
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 117.66 | |||||
| Equity-to-Asset | 0.21 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 30.8 | |||||
| 3-Year EPS without NRI Growth Rate | -40.9 | |||||
| 3-Year FCF Growth Rate | 25 | |||||
| 3-Year Book Growth Rate | -32.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.58 | |||||
| 9-Day RSI | 42.82 | |||||
| 14-Day RSI | 48.1 | |||||
| 3-1 Month Momentum % | 118.45 | |||||
| 6-1 Month Momentum % | 377.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.92 | |||||
| Quick Ratio | 0.92 | |||||
| Cash Ratio | 0.9 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20 | |||||
| Shareholder Yield % | 0.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -157.89 | |||||
| ROA % | -108.89 | |||||
| ROIC % | -88.11 | |||||
| 3-Year ROIIC % | -85.6 | |||||
| ROC (Joel Greenblatt) % | -2334.33 | |||||
| ROCE % | -69.58 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 39.31 | |||||
| Price-to-Tangible-Book | 39.79 | |||||
| EV-to-EBIT | -19.16 | |||||
| EV-to-EBITDA | -19.23 | |||||
| EV-to-FCF | -21.42 | |||||
| Earnings Yield (Greenblatt) % | -5.21 | |||||
| FCF Yield % | -4.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Corvus Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.835 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 48.1 | ||
| 14-Day ATR (€) | 0.275642 | ||
| 20-Day SMA (€) | 8.1705 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 1.218 - 9 | ||
| Shares Outstanding (Mil) | 64.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Corvus Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Corvus Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Corvus Pharmaceuticals Inc Frequently Asked Questions
What is Corvus Pharmaceuticals Inc(FRA:C17)'s stock price today?
The current price of FRA:C17 is €7.56. The 52 week high of FRA:C17 is €9.00 and 52 week low is €1.22.
When is next earnings date of Corvus Pharmaceuticals Inc(FRA:C17)?
The next earnings date of Corvus Pharmaceuticals Inc(FRA:C17) is 2025-03-19 Est..
Does Corvus Pharmaceuticals Inc(FRA:C17) pay dividends? If so, how much?
Corvus Pharmaceuticals Inc(FRA:C17) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers